Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias B Stope

Showing results (31-40 of 120) with videos related to

Pageof 12
Sort By:
World Journal of Urology|May 7, 2014
Androgen receptor (AR) inhibitor ErbB3-binding protein-1 (Ebp1) is not targeted by the newly identified AR controlling signaling axis heat-shock protein HSP27 and microRNA miR-1 in prostate cancer cellsMatthias B Stope, Stefanie Peters, Hannah Großebrummel, et al.
Cancers|November 13, 2025
Non-Invasive Physical Plasma as an Oncological Therapy Option: Modulation of Cancer Cell Growth, Motility, and Metabolism Without Induction of Cancer Resistance FactorsYanqing Wang, Benedikt Eggers, Alexander Abazid, et al.
Antioxidants (Basel, Switzerland)|April 23, 2020
Gas Plasma-Treated Prostate Cancer Cells Augment Myeloid Cell Activity and CytotoxicitySander Bekeschus, Verena Ressel, Eric Freund, et al.
In Vivo (Athens, Greece)|December 28, 2018
Overexpression of MicroRNA-1 in Prostate Cancer Cells Modulates the Blood Vessel System of an <i>In Vivo</i> Hen's Egg Test-Chorioallantoic Membrane ModelArik Reuter, Axel Sckell, Lars-Ove Brandenburg, et al.
Anticancer Research|December 1, 2022
Evaluation of the Diagnostic Potential of Circulating MicroRNAs <i>miR-1</i> and <i>miR-21</i> in Patients With Ovarian CancerDamian J Ralser, Mateja Condic, Eva Egger, et al.
Journal of Neuroimmunology|October 12, 2016
Lack of Toll-like receptor 2 results in higher mortality of bacterial meningitis by impaired host resistanceMartin Böhland, Eugenia Kress, Matthias B Stope, et al.
Anticancer Research|June 26, 2024
Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and EnzalutamideJennifer H S Küster, Holger H H Erb, Hannes Ahrend, et al.
International Journal of Molecular Sciences|September 20, 2017
Cold Atmospheric Plasma in the Treatment of OsteosarcomaDenis Gümbel, Sander Bekeschus, Nadine Gelbrich, et al.
Archives of Gynecology and Obstetrics|September 18, 2016
The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical applicationMatthias B Stope, Dominique Koensgen, Jörg Weimer, et al.
Journal of Cancer Research and Clinical Oncology|September 23, 2022
Metabolic changes during prostate cancer development and progressionAlicia-Marie K Beier, Martin Puhr, Matthias B Stope, et al.
Pageof 12

Showing results (31-40 of 120) with videos related to

Sort By:
Pageof 12
World Journal of Urology|May 7, 2014
Androgen receptor (AR) inhibitor ErbB3-binding protein-1 (Ebp1) is not targeted by the newly identified AR controlling signaling axis heat-shock protein HSP27 and microRNA miR-1 in prostate cancer cellsMatthias B Stope, Stefanie Peters, Hannah Großebrummel, et al.
Cancers|November 13, 2025
Non-Invasive Physical Plasma as an Oncological Therapy Option: Modulation of Cancer Cell Growth, Motility, and Metabolism Without Induction of Cancer Resistance FactorsYanqing Wang, Benedikt Eggers, Alexander Abazid, et al.
Antioxidants (Basel, Switzerland)|April 23, 2020
Gas Plasma-Treated Prostate Cancer Cells Augment Myeloid Cell Activity and CytotoxicitySander Bekeschus, Verena Ressel, Eric Freund, et al.
In Vivo (Athens, Greece)|December 28, 2018
Overexpression of MicroRNA-1 in Prostate Cancer Cells Modulates the Blood Vessel System of an <i>In Vivo</i> Hen's Egg Test-Chorioallantoic Membrane ModelArik Reuter, Axel Sckell, Lars-Ove Brandenburg, et al.
Anticancer Research|December 1, 2022
Evaluation of the Diagnostic Potential of Circulating MicroRNAs <i>miR-1</i> and <i>miR-21</i> in Patients With Ovarian CancerDamian J Ralser, Mateja Condic, Eva Egger, et al.
Journal of Neuroimmunology|October 12, 2016
Lack of Toll-like receptor 2 results in higher mortality of bacterial meningitis by impaired host resistanceMartin Böhland, Eugenia Kress, Matthias B Stope, et al.
Anticancer Research|June 26, 2024
Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and EnzalutamideJennifer H S Küster, Holger H H Erb, Hannes Ahrend, et al.
International Journal of Molecular Sciences|September 20, 2017
Cold Atmospheric Plasma in the Treatment of OsteosarcomaDenis Gümbel, Sander Bekeschus, Nadine Gelbrich, et al.
Archives of Gynecology and Obstetrics|September 18, 2016
The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical applicationMatthias B Stope, Dominique Koensgen, Jörg Weimer, et al.
Journal of Cancer Research and Clinical Oncology|September 23, 2022
Metabolic changes during prostate cancer development and progressionAlicia-Marie K Beier, Martin Puhr, Matthias B Stope, et al.
Pageof 12